BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, Kawata T, Azuma I, Toyoshima K, Seya T. Simulta-neous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun. 2003;71:4238-4249. [PMID: 12874299 DOI: 10.1128/iai.71.8.4238-4249.2003] [Cited by in Crossref: 124] [Cited by in F6Publishing: 55] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 2011;6:e18833. [PMID: 21533081 DOI: 10.1371/journal.pone.0018833] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
2 Tajiri K, Imanaka-Yoshida K, Tsujimura Y, Matsuo K, Hiroe M, Aonuma K, Ieda M, Yasutomi Y. A New Mouse Model of Chronic Myocarditis Induced by Recombinant Bacille Calmette-Guèrin Expressing a T-Cell Epitope of Cardiac Myosin Heavy Chain-α. Int J Mol Sci 2021;22:E794. [PMID: 33466825 DOI: 10.3390/ijms22020794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Matsuo K, Yasutomi Y. Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control. Tuberc Res Treat 2011;2011:574591. [PMID: 22567267 DOI: 10.1155/2011/574591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
4 Buonaguro L, Pulendran B. Immunogenomics and systems biology of vaccines. Immunol Rev 2011;239:197-208. [PMID: 21198673 DOI: 10.1111/j.1600-065X.2010.00971.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
5 Gein SV, Kuyukina MS, Ivshina IB, Baeva TA, Chereshnev VA. In vitro cytokine stimulation assay for glycolipid biosurfactant from Rhodococcus ruber: role of monocyte adhesion. Cytotechnology 2011;63:559-66. [PMID: 21858499 DOI: 10.1007/s10616-011-9384-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
6 Begum NA, Ishii K, Kurita-Taniguchi M, Tanabe M, Kobayashi M, Moriwaki Y, Matsumoto M, Fukumori Y, Azuma I, Toyoshima K, Seya T. Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages. Infect Immun 2004;72:937-48. [PMID: 14742539 DOI: 10.1128/IAI.72.2.937-948.2004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
7 Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 2018;7:e1526250. [PMID: 30524908 DOI: 10.1080/2162402X.2018.1526250] [Cited by in Crossref: 90] [Cited by in F6Publishing: 44] [Article Influence: 22.5] [Reference Citation Analysis]
8 Bhatnagar N, Kim KH, Subbiah J, Park BR, Ko EJ, Seong BL, Kang SM. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice. Antiviral Res 2021;197:105229. [PMID: 34933043 DOI: 10.1016/j.antiviral.2021.105229] [Reference Citation Analysis]
9 Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 2014;3:e29179. [PMID: 25083332 DOI: 10.4161/onci.29179] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
10 van Puffelen JH, Keating ST, Oosterwijk E, van der Heijden AG, Netea MG, Joosten LAB, Vermeulen SH. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol 2020;17:513-25. [PMID: 32678343 DOI: 10.1038/s41585-020-0346-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
11 Stathopoulos A, Pretto C, Devillers L, Pierre D, Hofman FM, Epstein AL, Farghadani H, Kruse CA, Jadus MR, Chen TC, Schijns VE. Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. J Clin Cell Immunol 2012;Suppl 5:004. [PMID: 24955288 DOI: 10.4172/2155-9899.S5-004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
12 Tomita Y, Watanabe E, Shimizu M, Negishi Y, Kondo Y, Takahashi H. Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells. Cancer Immunol Immunother 2019;68:1605-19. [PMID: 31531696 DOI: 10.1007/s00262-019-02396-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 Back YW, Choi S, Choi HG, Shin KW, Son YJ, Paik TH, Kim HJ. Cell wall skeleton of Mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing Th1 and Th17 responses. PLoS One 2019;14:e0213536. [PMID: 30849108 DOI: 10.1371/journal.pone.0213536] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Cardillo F, Bonfim M, da Silva Vasconcelos Sousa P, Mengel J, Ribeiro Castello-Branco LR, Pinho RT. Bacillus Calmette-Guérin Immunotherapy for Cancer. Vaccines (Basel) 2021;9:439. [PMID: 34062708 DOI: 10.3390/vaccines9050439] [Reference Citation Analysis]
15 Peng Y, Gong JP, Liu CA, Li XH, Gan L, Li SB. Expression of toll-like receptor 4 and MD-2 gene and protein in Kupffer cells after ischemia-reperfusion in rat liver graft. World J Gastroenterol 2004; 10(19): 2890-2893 [PMID: 15334694 DOI: 10.3748/wjg.v10.i19.2890] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
16 Postól E, Meyer A, Cardillo F, de Alencar R, Pessina D, Nihei J, Mariano M, Mengel J. Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production. Immunology 2008;125:184-96. [PMID: 18397273 DOI: 10.1111/j.1365-2567.2008.02835.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lee KS, Scanga CA, Bachelder EM, Chen Q, Snapper CM. TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell Immunol 2007;245:103-10. [PMID: 17521621 DOI: 10.1016/j.cellimm.2007.04.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
18 Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2013;2:e25238. [PMID: 24083080 DOI: 10.4161/onci.25238] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 11.8] [Reference Citation Analysis]
19 Kativhu CL, Libraty DH. A Model to Explain How the Bacille Calmette Guérin (BCG) Vaccine Drives Interleukin-12 Production in Neonates. PLoS One 2016;11:e0162148. [PMID: 27571272 DOI: 10.1371/journal.pone.0162148] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
20 Spanou E, Kalisperati P, Pateras IS, Papalampros A, Barbouti A, Tzioufas AG, Kotsinas A, Sougioultzis S. Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract. Front Genet 2017;8:65. [PMID: 28611823 DOI: 10.3389/fgene.2017.00065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
21 Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci 2015;106:1659-68. [PMID: 26395101 DOI: 10.1111/cas.12824] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
22 Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:894-907. [PMID: 23162757 DOI: 10.4161/onci.20931] [Cited by in Crossref: 141] [Cited by in F6Publishing: 136] [Article Influence: 141.0] [Reference Citation Analysis]
23 Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 2013;119:421-75. [PMID: 23870514 DOI: 10.1016/B978-0-12-407190-2.00007-1] [Cited by in Crossref: 305] [Cited by in F6Publishing: 164] [Article Influence: 38.1] [Reference Citation Analysis]
24 Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1:949-964. [PMID: 20563267 DOI: 10.2217/imt.09.70] [Cited by in Crossref: 159] [Cited by in F6Publishing: 150] [Article Influence: 14.5] [Reference Citation Analysis]
25 Schreiber F, Huo Z, Giemza R, Woodrow M, Fenner N, Stephens Z, Dougan G, Prideaux S, Castello-Branco LR, Lewis DJ. An investigation of clinical and immunological events following repeated aerodigestive tract challenge infections with live Mycobacterium bovis Bacille Calmette Guérin. Vaccine 2010;28:5427-31. [PMID: 20558246 DOI: 10.1016/j.vaccine.2010.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Huante MB, Gupta S, Calderon VC, Koo SJ, Sinha M, Luxon BA, Garg NJ, Endsley JJ. Differential inflammasome activation signatures following intracellular infection of human macrophages with Mycobacterium bovis BCG or Trypanosoma cruzi. Tuberculosis (Edinb) 2016;101S:S35-44. [PMID: 27733245 DOI: 10.1016/j.tube.2016.09.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
27 Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 2009;65:98R-105R. [PMID: 19918215 DOI: 10.1203/PDR.0b013e31819f195d] [Cited by in Crossref: 82] [Cited by in F6Publishing: 46] [Article Influence: 6.8] [Reference Citation Analysis]
28 Seledtsov VI, Goncharov AG, Seledtsova GV. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum Vaccin Immunother 2015;11:851-69. [PMID: 25933181 DOI: 10.1080/21645515.2015.1009814] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
29 Vinderola G, Matar C, Perdigon G. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol 2005;12:1075-84. [PMID: 16148174 DOI: 10.1128/CDLI.12.9.1075-1084.2005] [Cited by in Crossref: 99] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
30 Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93:847-863. [PMID: 23475577 DOI: 10.1189/jlb.1012501] [Cited by in Crossref: 188] [Cited by in F6Publishing: 175] [Article Influence: 20.9] [Reference Citation Analysis]
31 Whang YM, Jin SB, Park SI, Chang IH. MEK inhibition enhances efficacy of bacillus Calmette-Guérin on bladder cancer cells by reducing release of Toll-like receptor 2-activated antimicrobial peptides. Oncotarget 2017;8:53168-79. [PMID: 28881802 DOI: 10.18632/oncotarget.18230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
32 Rodríguez-Güell E, Agustí G, Corominas M, Cardona PJ, Luquin M, Julián E. Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton. Clin Vaccine Immunol 2008;15:893-6. [PMID: 18337379 DOI: 10.1128/CVI.00477-07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
33 Chiang CL, Kandalaft LE. In vivo cancer vaccination: Which dendritic cells to target and how? Cancer Treat Rev 2018;71:88-101. [PMID: 30390423 DOI: 10.1016/j.ctrv.2018.10.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
34 Pai RK, Pennini ME, Tobian AA, Canaday DH, Boom WH, Harding CV. Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect Immun 2004;72:6603-14. [PMID: 15501793 DOI: 10.1128/IAI.72.11.6603-6614.2004] [Cited by in Crossref: 116] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
35 Kim KH, Lee YT, Park Y, Ko EJ, Jung YJ, Kim YJ, Jo EK, Kang SM. BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection. Biomedicines 2021;9:516. [PMID: 34063125 DOI: 10.3390/biomedicines9050516] [Reference Citation Analysis]
36 Bourguignon LY, Wong G, Earle CA, Xia W. Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion. Cytoskeleton (Hoboken) 2011;68:671-93. [PMID: 22031535 DOI: 10.1002/cm.20544] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
37 Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J, Akazawa T, Matsumoto M, Seya T, Wada M, Toyoshima K. Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surg Today 2009;39:194-200. [PMID: 19280277 DOI: 10.1007/s00595-008-3826-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
38 Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, Touray E, Philbin VJ, Mancuso C, Kampmann B, Whittle H, Jaye A, Flanagan KL, Levy O. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 2011;6:e18185. [PMID: 21533209 DOI: 10.1371/journal.pone.0018185] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 7.8] [Reference Citation Analysis]
39 Schierloh P, Yokobori N, Alemán M, Landoni V, Geffner L, Musella RM, Castagnino J, Baldini M, Abbate E, de la Barrera SS, Sasiain MC. Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving Toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy. Infect Immun 2007;75:5325-37. [PMID: 17709420 DOI: 10.1128/IAI.00381-07] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
40 Flanagan KL, Burl S, Lohman-Payne BL, Plebanski M. The challenge of assessing infant vaccine responses in resource-poor settings. Expert Rev Vaccines 2010;9:665-74. [PMID: 20518720 DOI: 10.1586/erv.10.41] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhang MH, Slaby EM, Stephanie G, Yu C, Watts DM, Liu H, Szeto GL. Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering. Front Immunol 2020;11:560. [PMID: 32425924 DOI: 10.3389/fimmu.2020.00560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008;7:3642-53. [PMID: 19001446 DOI: 10.1158/1535-7163.MCT-08-0582] [Cited by in Crossref: 79] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
43 Versiani AF, Astigarraga RG, Rocha ES, Barboza AP, Kroon EG, Rachid MA, Souza DG, Ladeira LO, Barbosa-Stancioli EF, Jorio A, Da Fonseca FG. Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice. J Nanobiotechnology 2017;15:26. [PMID: 28376812 DOI: 10.1186/s12951-017-0259-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
44 Zaba LC, Smith GP, Sanchez M, Prystowsky SD. Dendritic cells in the pathogenesis of sarcoidosis. Am J Respir Cell Mol Biol 2010;42:32-9. [PMID: 19372243 DOI: 10.1165/rcmb.2009-0033TR] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
45 Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:699-716. [PMID: 22934262 DOI: 10.4161/onci.20696] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 153.0] [Reference Citation Analysis]
46 Fávaro WJ, Nunes OS, Seiva FR, Nunes IS, Woolhiser LK, Durán N, Lenaerts AJ. Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer. Infect Agent Cancer 2012;7:14. [PMID: 22709446 DOI: 10.1186/1750-9378-7-14] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
47 Ozgür A, Xiang Z, Radev DR, He Y. Mining of vaccine-associated IFN-γ gene interaction networks using the Vaccine Ontology. J Biomed Semantics 2011;2 Suppl 2:S8. [PMID: 21624163 DOI: 10.1186/2041-1480-2-S2-S8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
48 Yang Y, Wolfram J, Fang X, Shen H, Ferrari M. Polyarginine induces an antitumor immune response through binding to toll-like receptor 4. Small 2014;10:1250-4. [PMID: 24323884 DOI: 10.1002/smll.201302887] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
49 Buonaguro L, Wang E, Tornesello ML, Buonaguro FM, Marincola FM. Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol. 2011;5:146. [PMID: 21933421 DOI: 10.1186/1752-0509-5-146] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
50 Darboe F, Adetifa JU, Reynolds J, Hossin S, Plebanski M, Netea MG, Rowland-Jones SL, Sutherland JS, Flanagan KL. Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette-Guérin Russia Vaccination. Front Immunol 2017;8:1092. [PMID: 28951731 DOI: 10.3389/fimmu.2017.01092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
51 Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2020;9:1777625. [PMID: 32934882 DOI: 10.1080/2162402X.2020.1777625] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 12.5] [Reference Citation Analysis]
52 Nouri Y, Weinkove R, Perret R. T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. J Immunother Cancer 2021;9:e003065. [PMID: 34799397 DOI: 10.1136/jitc-2021-003065] [Reference Citation Analysis]
53 Shannon JG, Howe D, Heinzen RA. Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule. Proc Natl Acad Sci U S A 2005;102:8722-7. [PMID: 15939879 DOI: 10.1073/pnas.0501863102] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
54 Anis MM, Fulton SA, Reba SM, Harding CV, Boom WH. Modulation of naive CD4+ T-cell responses to an airway antigen during pulmonary mycobacterial infection. Infect Immun 2007;75:2260-8. [PMID: 17296758 DOI: 10.1128/IAI.01709-06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
55 Kawahara M, Hasegawa N, Takaku H. Murine Splenic Natural Killer Cells Do Not Develop Immunological Memory after Re-Encounter with Mycobacterium bovis BCG. PLoS One 2016;11:e0152051. [PMID: 26999357 DOI: 10.1371/journal.pone.0152051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
56 Kettner S, Kalthoff F, Graf P, Priller E, Kricek F, Lindley I, Schweighoffer T. EWI-2/CD316 is an inducible receptor of HSPA8 on human dendritic cells. Mol Cell Biol 2007;27:7718-26. [PMID: 17785435 DOI: 10.1128/MCB.00180-07] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
57 Lu CC, Kuo HC, Wang FS, Jou MH, Lee KC, Chuang JH. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci 2014;16:159-77. [PMID: 25547486 DOI: 10.3390/ijms16010159] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]